Transketolase attenuates the chemotherapy sensitivity of glioma cells by modulating R-loop formation

Glioblastoma (GBM) is a highly lethal malignant brain tumor with poor survival rates, and chemoresistance poses a significant challenge to the treatment of patients with GBM. Here, we show that transketolase (TKT), a metabolic enzyme in the pentose phosphate pathway (PPP), attenuates the chemotherapy sensitivity of glioma cells in a manner independent of catalytic activity. Mechanistically, chemotherapeutic drugs can facilitate the translocation of TKT protein from the cytosol into the nucleus, where TKT physically interacts with XRN2 to regulate the resolution and removal of R-loops. Depletion of TKT leads to increased R-loop accumulation and genome instability, increasing the susceptibility of glioma cells to chemotherapy. In conclusion, our study reveals a non-metabolic function of TKT in regulating R-loop dynamics, genome instability, and chemotherapy sensitivity in gliomas.

Authors

Institutions

Publication Details

Journal
Cell Reports
Published
2025-01-01
DOI
https://doi.org/10.1016/j.celrep.2024.115142
Citations
7
Primary Topic
Cancer, Hypoxia, and Metabolism
Type
article
Field-Weighted Citation Impact
6.55

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Transketolase attenuates the chemotherapy sensitivity of glioma cells by modulating R-loop formation

Youjun Chu, Feng Yuan, Huaichao Zhang, Jinsen Zhang et al.
7 citations
Cell Reports
Cancer, Hypoxia, and Metabolism
6.55
article

Transketolase attenuates the chemotherapy sensitivity of glioma cells by modulating R-loop formation

Youjun Chu, Feng Yuan, Huaichao Zhang, Jinsen Zhang, Yonghe Wu, Tianping Peng, Hao Xu, Wei Hua, Minjie Fu, Licheng Zhang, Chao Gao, Mengli Zhang, Dan Ye, Pu Wang, Ying Mao
article en
7 citations

Abstract

Glioblastoma (GBM) is a highly lethal malignant brain tumor with poor survival rates, and chemoresistance poses a significant challenge to the treatment of patients with GBM. Here, we show that transketolase (TKT), a metabolic enzyme in the pentose phosphate pathway (PPP), attenuates the chemotherapy sensitivity of glioma cells in a manner independent of catalytic activity. Mechanistically, chemotherapeutic drugs can facilitate the translocation of TKT protein from the cytosol into the nucleus, where TKT physically interacts with XRN2 to regulate the resolution and removal of R-loops. Depletion of TKT leads to increased R-loop accumulation and genome instability, increasing the susceptibility of glioma cells to chemotherapy. In conclusion, our study reveals a non-metabolic function of TKT in regulating R-loop dynamics, genome instability, and chemotherapy sensitivity in gliomas.

Cell ReportsVol. 44(1)
Shanghai Medical College of Fudan University (CN), Fudan University (CN), ShanghaiTech University (CN), Obstetrics and Gynecology Hospital of Fudan University (CN), Shanghai Clinical Research Center (CN), Huashan Hospital (CN), Shanghai Center for Brain Science and Brain-Inspired Technology (CN)
National Natural Science Foundation of China, Chinese Academy of Meteorological Sciences, National Key Research and Development Program of China
Openalex Percentile: Top 4%
Cancer, Hypoxia, and Metabolism
6.55
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.